3SBio Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in the Peoples Republic of China. Its products are designed to address unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The companys principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin product to treat chemotherapy-induced thrombocytopenia, a deficiency of platelets. 3SBio also offers protein-based therapeutics, such as Intefen, a recombinant human interferon alpha-2a product for malignancies of the lymphatic or hematopoietic system, and viral infectious diseases; and Inleusin, a recombinant human interleukin-2 product for renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused by cancer and tuberculosis. In addition, it markets Tietai Iron Sucrose Supplement, an in-licensed product for the treatment of anemia. The companys product pipeline comprises Ferumoxytol, a next generation intravenous iron; a high dose (36,000 IU/vial) formulation EPIAO; and NuPIAO, a second-generation EPIAO product candidate. Its product pipeline also consists of NuLeusin, a next-generation Inleusin product candidate; TPIAO for idiopathic thrombocytopenic purpura; a human papilloma virus vaccine to prevent cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for rheumatoid arthritis and other autoimmune diseases. 3SBio sells its products through distributors to hospitals, clinics, and dialysis centers, as well as through distribution agreements with local agents. It has a development and commercialization agreement with AMAG Pharmaceuticals, Inc. for ferumoxytol. The company was founded in 1993 and is based in Shenyang, the Peoples Republic of China.

aaiPharma, Inc. operates as a science-based pharmaceutical company primarily in the United States and Europe. The company focuses on acquiring, improving, and marketing branded medicines in pain management and critical care. Its pain management products include Roxicodone tablets and immediate release oral.. Read More

Aastrom Biosciences, Inc. engages in developing autologous cell products for the repair or regeneration of human tissue. Its proprietary tissue repair cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. The companys TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. Aastroms development activities are focused on applying TRC technology to cardiac and vascular tissue regeneration. It focuses on cardiovascular regeneration and is conducting a Phase II clinical trial with dilated cardiomyopathy patients (the IMPACT-DCM clinical trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI clinical trial). The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.

Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. The companys product pipeline includes clinical oncology and cardiovascular product candidates.. Read More

ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It focuses on developing a portfolio of its four advanced product candidates, including Pimavanserin, which is in phase III development for Parkinsons disease psychosis; and a product candidate in phase II for chronic pain and a product candidate in phase I for glaucoma, each in collaboration with Allergan, Inc., as well as ACP-106 in IND-track development for neuropsychiatry and sleep indications. Pimavanserin is also in a phase II trial as a co-therapy in schizophrenia and in a proof-of-concept clinical study for sleep maintenance insomnia. ACADIA Pharmaceuticals development pipeline also consists of ACP-105 for endocrine indications in IND-track development stage; Serotonin program for neuropsychiatry and sleep indications in preclinical stage; pro-cognitive antipsychotic (PCAP) program for schizophrenia in preclinical stage; Muscarinic program for neuropsychiatry and other indications; and two series of compounds for Parkinsons disease. It has a collaboration agreement with Biovail Laboratories International SRL to co-develop and commercialize pimavanserin in the United States and Canada. The company, formerly known as Receptor Technologies, Inc., was founded in 1993 and is headquartered in San Diego, California.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C and HIV infection; and the development of antibacterials.. Read More

Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The companys lead product candidate is Fampridine-SR, which completed two positive Phase III clinical trials for the improvement of walking ability in patients with MS. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.

A development stage Company focusing on investing and commercializing novel technology platforms concerning the Life Sciences sector.

Adeona Pharmaceuticals, Inc., a development-stage specialty pharmaceutical company, focuses on the awareness, diagnosis, prevention, and treatment of subclinical zinc deficiency and chronic copper toxicity in the mature population. Such conditions may contribute to the progression of debilitating degenerative.. Read More

Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. It primarily focuses on cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company also develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. It also plans to develop and commercialize products for use in the treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, infarction, and burns. The company has research and license agreements with University of Massachusetts, Wake Forest University, WiCell Research Institute, Inc., Kirin Beer Kabushiki Kaisha, and Start Licensing. It also has a joint venture agreement with CHA Biotech Co., Ltd. to develop human blood cells and other clinical therapies based on the companys proprietary hemangioblast cell technology. Advanced Cell Technology, Inc. is headquartered in Worcester, Massachusetts.

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel drugs in the areas of infectious disease, oncology, and respiratory disease. Its lead candidate includes Cethromycin, a novel once-a-day oral antibiotic under review by the FDA for the treatment of mild-to-moderate community acquired pneumonia. Cethromycin has also completed Phase III clinical trials for the treatment of respiratory tract infections. The company also has an exclusive worldwide license agreement with Abbott Laboratories for the development and commercialization of Cethromycin. Advanced Life Sciences products under preclinical studies comprise ALS-357, a compound for the treatment of malignant melanoma; and ALS-886, a novel therapeutic for the treatment of inflammation-related tissue damage consisting of tissue damage associated with acute respiratory distress syndrome. Its products under preclinical studies also include product candidates derived from the companys natural products-based chemistry platform. Advanced Life Sciences has collaborations and license agreements with Wyeth Pharmaceuticals, University of Illinois at Chicago, Baxter International, National Institute of Allergy and Infectious Diseases, and Defence Science and Technology Laboratory of the United Kingdom. The company was founded in 1999 and is headquartered in Woodridge, Illinois.

Advaxis, Inc., a development stage biotechnology company, engages in the research and development of new cancer-fighting techniques primarily in the United States. The company develops cancer vaccines targeting cervical, head and neck, breast, prostate, and other cancers. Its products in development stage.. Read More

ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulations of chemotherapy drug vinorelbine to treat advanced non-small.. Read More

terna Zentaris Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for endocrine therapy and oncology. Its lead product candidates include cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist that has completed Phase III trial for benign prostatic hyperplasia (BPH) indication; and AEZS-108, a Phase II clinical trial product for the treatment of advanced ovarian and endometrial cancers. The company also develops drugs, which are in Phase II clinical trials, including Cetrorelix for endometriosis in Japan; Ozarelix for the treatment of BPH and prostate cancer; and Perifosine for various cancers. Its products under Phase I clinical trials also comprise AEZS-112 for oncology; and AEZS-130 for endocrinology. In addition, the companys product pipeline comprises AEZS-115, an LHRH antagonist for endometriosis and urology; AEZS-120, a urology vaccine; AEZS-126 Erk and PI3K inhibitors for oncology; AEZS-127 ErPC for oncology; and Ghrelin receptor ligands for endocrinology. Further, it offers Cetrotide for the treatment of infertility. terna Zentaris has partnership agreements with Shionogi and Co.; sanofi-aventis; ARES Trading S.A.; Nippon Kayaku Co. Ltd.; Spectrum Pharmaceuticals, Inc.; Handok Pharmaceuticals Co., Ltd.; and Keryx Biopharmaceuticals, Inc. The company sells its products in the United States, Canada, Switzerland, the United Kingdom, the Netherlands, and Japan. terna Zentaris was founded in 1990 and is headquartered in Quebec, Canada.

Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The companys lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure and cancer. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide. The company was founded in 2001 and is based in Palo Alto, California.

Alfacell Corporation, a development stage company, engages in the discovery and development of therapeutic drugs for the treatment of cancer and other pathological conditions primarily in the United States. The companys primary drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. It also completed preparing new drug application for unresectable malignant mesothelioma. In addition, the company is conducting a Phase I/II clinical trial for lung cancer and other solid tumors. Alfacell was founded in 1981 and is headquartered in Somerset, New Jersey.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics based on RNA interference (RNAi). The companys lead RNAi therapeutic program includes ALN-RSV01, a phase II clinical trial product for the treatment of respiratory syncytial virus (RSV) infection. It develops RNAi therapeutics for the treatment of liver cancers, hypercholesterolemia, Huntingtons disease, and transthyretin amyloidosis. The company has collaboration and license agreements with Isis Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited for the discovery, development, and commercialization of RNAi therapeutics; with Novartis Pharma AG to discover, develop, commercialize, and manufacture compounds that function through the mechanism of RNAi; and with Biogen Idec Inc. for the discovery and development of therapeutics based on RNAi for the treatment of progressive multifocal leukoencephalopathy. It also holds license and collaboration agreements with Medtronic, Inc. to develop therapeutic products for the treatment of neurodegenerative disorders; with Kyowa Hakko for the development and commercialization of ALN-RSV01; with Cubist Pharmaceuticals, Inc. to develop and commercialize therapeutic products for the treatment of RSV; and with F. Hoffmann-La Roche Ltd. to develop and commercialize therapeutics in the areas of oncology, respiratory, metabolic, and liver diseases. The companys joint venture, Regulus Therapeutics LLC, focuses on the discovery, development, and commercialization of microRNA therapeutic that targets miR-122 for the treatment of hepatitis C virus infection. In addition, it grants its intellectual property rights licenses to biotechnology companies for the development and commercialization of RNAi therapeutics; and to research companies that commercialize RNAi reagents or services under its research product licenses. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alseres Pharmaceuticals, Inc., a biotechnology company, develops diagnostic and therapeutic products primarily for disorders in the central nervous system. The companys product pipeline is based on proprietary technology platforms, such as molecular imaging program that focuses on the diagnosis of Parkinsons disease (PD), attention deficit hyperactivity disorder (ADHD), and dementia with lewy bodies (DLB); regenerative therapeutics program, which focuses on nerve repair and restoring movement, and sensory function in patients; and neurodegenerative disease program focusing on treating the symptoms of PD, and slowing or stopping the progression of PD. Its products based on molecular imaging program include Altropane for the diagnosis of PD in Phase III clinical trial, for the diagnosis of ADHD in Phase II clinical trial, and for the diagnosis of DLB in preclinical stage; and Technetium-based agents for the diagnosis of PD/ADHD/DLB in preclinical trial. The companys product candidates based on regenerative therapeutics program comprise Cethrin for the treatment of acute spinal cord injury (SCI) in Phase I/IIa trial, as well as INOSINE for the treatment of SCI/stroke, Oncomodulin for treating eye diseases, and Rho Inhibitor for bone repair, which are under preclinical trials. It is also developing Dopamine Transporter blockers for the treatment of PD, which are in preclinical trial, based on neurodegenerative disease program. Alseres Pharmaceuticals has collaborations with MDS Nordion, Inc., which manufactures the Altropane molecular imaging agent; and Organix, Inc. that provides non-radioactive Altropane for FDA mandated studies, and synthesizes the companys compounds for the treatment of PD and for axon regeneration. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is headquartered in Hopkinton, Massachusetts.

Altus Pharmaceuticals Inc., together with its subsidiaries, focuses on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. Its lead product candidates include ALTU-238, completed Phase II clinical trial in adults, is a crystallized formulation of human growth hormone for the treatment of hormone deficiency and related disorders; and ALTU-237, completed Phase I clinical trial, which is used for the treatment of hyperoxalurias and kidney stones. The companys preclinical research and development programs include ALTU-236, an orally-administered enzyme replacement therapy product candidate designed to reduce the long-term effects associated with excess levels of phenylalanine; and ALTU-242, an orally-administered enzyme product candidate designed to reduce the long-term effects associated with excess levels of urate, which precipitates and forms crystals in joints causing a painful erosive arthritis, known as gout. Its product candidates are designed to substitute a protein that is in short supply in the body, degrade toxic metabolites in the gut, and remove them from the blood stream. Altus Pharmaceuticals has a license agreement with Cystic Fibrosis Foundation Therapeutics, Inc. to use its intellectual property to develop, manufacture, and commercialize any product using, in any combination, the three active pharmaceutical ingredients which comprise Trizytek. Altus Pharmaceuticals Inc. was formerly known as Altus Biologics Inc. and changed its name to Altus Pharmaceuticals Inc. in May 2004. The company was incorporated in 1992 and is based in Waltham, Massachusetts.

Amarillo Biosciences, Inc. engages in the development of biologics for the treatment of human and animal diseases. The company develops low-dose oral interferon alpha, which is in the Phase II clinical trial for the treatment of influenza, chronic obstructive pulmonary disease, and oral warts in HIV positive.. Read More

Amazon Biotech, Inc., a development stage company, engages in the research and development of natural drugs in the United States. It owns rights to an investigational drug candidate, AMZ0026, which is a naturally derived pharmaceutical drug compound made up of plant substances for the treatment of HIV/AIDS. The.. Read More

American Oriental Bioengineering, Inc., along with its subsidiaries, engages in the development, manufacture, and commercialization of a range of pharmaceutical and healthcare products. It offers prescription and over-the-counter pharmaceutical products, and nutraceutical products. The companys prescription pharmaceutical products include Shuanghuanlian Lyophilized (SHL) injection powder, an anti-viral injection for the treatment of flu symptoms, upper respiratory infections, mild pneumonia, and tonsillitis; and Cease Enuresis Soft Gel (CE Gel) to alleviate pediatric bedwetting. American Oriental Bioengineering markets the SHL products under SHJ brand name; the CE Gel under the brand name, Three Happines; and AOBO-001, an oral capsule developed from traditional Chinese herbal medicine for the treatment of urinary incontinence, which is in the phase one clinical trial. Its over-the-counter pharmaceutical products comprise Cease Enuresis Patch for the treatment of bedwetting and incontinence; Jinji Capsule for the treatment of endometritis, annexitis, and pelvic inflammations; Jinji Yimucao for the treatment of premenstrual syndrome (PMS), and other PMS and menopause-related symptoms; and Boke nasal spray for the treatment of sinus congestion from common cold, stuffy nose, chronic rhinitis, allergic rhinitis, and nasosinusitis. The companys nutraceutical products include soybean peptide based drinks, tablets, powder, and instant coffee for health and well-being. American Oriental Bioengineering sells its products primarily to hospitals, clinics, pharmacies, and retail outlets in China. The company is based in Shenzhen, the Peoples Republic of China.

Amgen Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products primarily in the areas of supportive cancer care, nephrology, and inflammation. Its.. Read More

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs, known as pharmacological chaperones, for the treatment of various human genetic diseases. Pharmacological chaperones selectively bind to the target.. Read More

Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with.. Read More

Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, an oral toll-like receptor 7 agonist prodrug for.. Read More

Anesiva, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutic treatments for pain management worldwide. Its lead product candidate includes Adlea, which completed multiple Phase II and Phase III trials for post-surgical, musculoskeletal, and neuropathic pain... Read More

AngioGenex, Inc., a development stage biopharmaceutical company, engages in the research to develop anti-cancer strategies using the field of antiangiogenesis. Its programs focus on the discovery and development of orally active anti-cancer drugs that act by modulating the action of the Id proteins; the.. Read More

Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company offers ORTHOVISC, an HA product used in the treatment of.. Read More

Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its products include Oncophage (vitespen), a patient-specific therapeutic cancer vaccine registered for use in the Russia Federation, as well as under review by the European Medicines Agency for the treatment of kidney cancer patients with earlier-stage disease. The company tested Oncophage in phase 3 clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and phase 1 and phase 2 clinical trials for various indications, as well as in phase 2 clinical trial for the treatment of recurrent glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is used in various vaccines under development in trials for diseases, such as hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimers disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics, Inc. in February 2000. Antigenics was founded in 1994 and is headquartered in Lexington, Massachusetts.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of genetically-targeted therapies for heart failure and other cardiovascular diseases in the United States. The companys lead product candidate includes Gencaro, a pharmacologically beta-blocker and mild vasodilator for the treatment of chronic heart failure and other indications. It also focuses on the development of NU172, a short-acting anticoagulant used during medical or surgical procedures, which has completed Phase Ib clinical study. ARCA biopharma has a collaboration agreement with LabCorp to develop the Gencaro Test, a companion test for the genetic markers that predict clinical response to Gencaro. The company is headquartered in Broomfield, Colorado.

ARIAD Pharmaceuticals, Inc., together with its subsidiaries, discovers and develops medicines to treat cancers by regulating cell signaling with small molecules in the United States and Europe. The companys cancer product candidate includes deforolimus, a potent protein mTOR inhibitor for the treatment of solid tumors, such as sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas. It offers Phase 3 clinical trial of oral deforolimus in patients with metastatic soft-tissue and bone sarcomas; and multiple clinical trials of deforolimus, including Phase 2 clinical trials in endometrial, breast, and prostate cancers. The company studies deforolimus as a single agent in multiple Phase 1 and Phase 2 clinical trials in patients with sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas. It conducts various multi-center Phase 1b trials of deforolimus in combination with anti-cancer therapies, which focuses on patients with various types of solid tumors; and Phase 1 trials of AP24534 that is used in the treatment of drug-resistant and refractory chronic myeloid leukemia, and hematological cancers. The company licenses NF-kB cell-signaling technology and treatment methods to pharmaceutical and biotechnology companies that conducts research to discover and develop drugs that modulate NF-kB cell-signaling and/or marketing such drugs; and ARGENT cell-signaling regulation technology for various pharmaceutical and biotechnology companies for research and development of therapeutic vaccines, and gene and cell therapy. It has a license agreement with Medinol, Ltd. to develop and commercialize deforolimus-eluting stents and other medical devices to prevent restenosis or reblockage of injured vessels; and collaboration agreement with Merck & Co., Inc. to develop deforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is based in Cambridge, Massachusetts.

Arno Therapeutics, Inc., a development stage company, engages in developing and commercializing products for the treatment of cancer. Its lead compound, AR-67, has completed Phase I clinical studies for the treatment of solid tumors. The company is also developing AR-12 and AR-42, which are novel pre-clinical.. Read More

Artes Medical, Inc., a medical technology company, focuses on the developing, manufacturing, and commercializing injectable aesthetic products for the dermatology and plastic surgery markets in the United States. It offers ArteFill, a non-resorbable aesthetic injectable implant for the correction of facial.. Read More

ASI Technology Corporation operates as a specialty finance and technology development company. It provides real estate, corporate, and various other loans. The companys real estate loans are advanced to bridge finance projects during the development and permitting phase. In addition, ASI Technology focuses on the.. Read More

Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic product candidates in multiple disease areas in the United States. Its product pipeline includes MultiStem, a nonembryonic stem cell product candidate for the treatment of multiple disease indications. The company.. Read More

Auriga Laboratories, Inc., a specialty pharmaceutical company, engages in the development, commercialization, and licensing of pharmaceutical products in the areas of respiratory, dermatology, and anti-infective therapeutic categories. The company's product line includes Extendryl for the treatment of cough,.. Read More

AutoImmune, Inc., a development stage company, develops products for the treatment of autoimmune and other cell-mediated inflammatory diseases and conditions. It offers a dietary supplement under Colloral, The Collagen Solution, and Vital 3 brand names for treating the signs and symptoms of rheumatoid arthritis. The companys products in development include MBP8298, which is in Phase III trials for the treatment of secondary progressive multiple sclerosis, as well as in Phase II clinical trials for relapsing-remitting multiple sclerosis; Oral Copaxone that is in preclinical stage for the treatment of multiple sclerosis; and AI 401, which is in phase III trails for the treatment of Type I diabetes. AutoImmune has a joint venture with Deseret Laboratories, Inc. by forming an entity, Colloral LLC, to manufacture, market, and sell Colloral as a dietary supplement. It also has collaboration agreements with The Brigham and Womens Hospital and Eli Lilly and Company. The company, formerly AutoImmune Technologies, Inc., was founded in 1988 and is based in Pasadena, California.

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The companys autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

BELLUS Health, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of products to provide health solutions to address critical medical needs. The company involves in pharmaceutical and nutraceutical businesses. Its product candidates include eprodisate, which has.. Read More

Beluga Composites Corp, formerly Biocircuits Corporation, was founded to develop new immunodiagnostic testing systems. Immunodiagnostic tests, or assays, are performed on samples of bodily fluids to diagnose a variety of infectious diseases and other conditions, such as endocrine dysfunctions, and to conduct.. Read More

Bio-Bridge Science, Inc., a development stage company, engages in the commercial development of biological products for the prevention and treatment of human infectious diseases. It develops and commercializes HIV-PV Vaccine I to prevent and treat infection by the human immunodeficiency virus (HIV) in mainland.. Read More

BioCryst Pharmaceuticals, Inc., a biotechnology company, engages in the design, optimization, and development of drugs that block key enzymes involved in cancer, viral infections, and autoimmune diseases. It integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals. The companys product candidates include forodesine HCl, a transition-state analog inhibitor of the target enzyme purine nucleoside phosphorylase (PNP), which is in Phase IIb clinical trial for patients with Cutaneous T-cell Lymphoma (CTCL); and in a Phase II trial with an oral formulation in Chronic Lymphocytic Leukemia (CLL). Its Forodesine HCl product is used for three indications: T-cell non-Hodgkin lymphoma, including CTCL; CLL and related leukemias, including T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for the treatment of B-cell acute lymphoblastic leukemia. The company also provides peramivir, an inhibitor of influenza neuraminidase, which completed Phase II clinical trial for the treatment of influenza with two parenteral formulations, intramuscular and intravenous. In addition, it offers BCX-4208/R3421, a second generation PNP inhibitor, which is in the Phase IIa clinical trial for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases. The company has collaborative and other research and development contracts with Shionogi & Co., Ltd.; U.S. Department of Health and Human Services; Green Cross Corporation; Mundipharma International Holdings Limited; F.Hoffmann-La Roche Ltd. and Hoffman-La Roche Inc.; Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.; The University of Alabama at Birmingham; and Emory University. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is based in Birmingham, Alabama.

BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB. The companys products/formulations also include BEMA Buprenorphine, which is under preparation for phase 2 for moderate to severe and acute pain. Its lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. The company also has a Bioral formulation, which is in initial in vitro studies for the intranasal administration of Amphotericin B to treat chronic rhinosinusitis. BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease. The company was founded in 1997 and is based in Raleigh, North Carolina.

Biogen Idec Inc., a biotechnology company, develops, manufactures, and commercializes novel therapeutics in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally. The companys marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, low-grade or follicular, CD20-positive, and B-cell Non-Hodgkins Lymphoma (NHL); TYSABRI to treat relapsing MS; and FUMADERM for the treatment of severe psoriasis. Its products under development consist of BG-12, a Phase III clinical trial product for the treatment of MS; Anti-CD80 MAb, a Phase III clinical trial product for the treatment of relapsed NHL; Anti-CD23 MAb, a Phase II/III clinical trial product for the treatment of relapsed or refractory chronic lymphocytic leukemia; Humanized Anti-CD20 MAb, a Phase III clinical trial product for the treatment of rheumatoid arthritis and lupus nephritis; Lixivaptan, a Phase III clinical drug for the treatment of Acute Hyponatremia; and ADENTRI, a Phase III clinical trial product for acute decompensated heart failure patients with renal insufficiency. The companys products under preclinical stage comprise BIIB014, Daclizumab, CDP323, Humanized Anti-CD20 MAb, PEG-IFN beta 1a, Neublastin, and LINGO for neurology; Volociximab, Hsp90 Inhibitor, GA101, Anti-IGF-1R, Anti-CRIPTO, RAF Inhibitor, and Anti-Fn14 for oncology; BG-12, Anti-TWEAK, Anti-CD40L Fab, and Anti-FcRn for autoimmune and inflammatory diseases; and ADENTRI and Aviptadil for cardiovascular diseases. It has collaboration agreements with Neurimmune SubOne AG; Cardiokine Biopharma LLC; mondoBIOTECH, AG; Alnylam Pharmaceuticals, Inc.; UCB, S.A.; Facet Biotech Corporation; Sunesis Pharmaceuticals, Inc.; Vernalis plc; Vetter Pharma-Fertigung GmbH & Co. KG; and Schering AG, as well as a definitive agreement with AVEO Pharmaceuticals Inc. The company was founded in 1985 and is based in Cambridge, Massachusetts.

Bioheart, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease in the United States and Europe. Its lead product candidate is MyoCell, a clinical muscle-derived cell therapy designed to populate regions of scar tissue in a patients heart with autologous muscle cells for improving cardiac function in chronic heart failure patients. The companys products under development include Bioheart Acute Cell Therapy, an autologous adipose cell treatment for acute heart damage; TGI 1200 Adipose Tissue Processing System, an automated device for the rapid processing of patient derived fat tissue; and MyoCell SDF-1, an autologous cell therapy for the treatment of severe chronic damage to the heart and cells modified to express angiogenic factors. Its product candidates also include MyoCath, a disposable endoventricular catheter used for the delivery of biologic solutions to the myocardium; MyoCath II, a second generation disposable endoventricular catheter to provide multidirectional cell injection for the delivery of biologic solutions to the myocardium; and BioPace for the treatment of chronic abnormal heart rhythm. The company was founded in 1999 and is headquartered in Sunrise, Florida.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises approved products and multiple investigational product candidates. The companys approved products include Naglazyme (galsulfase), a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used to treat genetic disease called mucopolysaccharidosis (MPS)VI; Kuvan (sapropterin dihydrochloride), a proprietary synthetic oral form of 6R-BH4, a naturally occurring enzyme co-factor for phenylalanine hydroxylase indicated for patients with Phenylketonuria (PKU); and Aldurazyme (laronidase) that is used to treat mucopolysaccharidosis I caused by the deficiency of a lysosomal enzyme called alpha-L-iduronidase. Its clinical development products comprise various product candidates for the treatment of genetic diseases, which include PEG-PAL, an enzyme substitution therapy under Phase I clinical development to treat phenylketonurics, which are not responsive to Kuvan; 6R-BH4, a Phase II clinical development product for the treatment of multiple cardiovascular indications, including sickle cell disease; and GALNS, an enzyme replacement therapy for MPS Type IV or Morquio Syndrome Type A (MPS IV A), a lysosomal storage disease. In addition, the company is conducting preclinical development of various other enzyme product candidates for genetic and other diseases, including a small molecule for the treatment of Duchenne muscular dystrophy. Further, BioMarin holds rights to receive royalties related to Orapred and Orapred ODT as a result of sublicense of North American rights. The company sells its products to specialty pharmacies, hospitals acting as retailers, and pharmaceutical wholesalers in the United States, Europe, and internationally. It has a strategic alliance with Merck Serono S.A. and joint venture with Genzyme Corporation. The company was founded in 1996 and is headquartered in Novato, California.

Bio-Matrix Scientific Group, Inc., a development stage company, engages in the design, development, and marketing of medical devices, specifically disposable instruments used in stem cell extraction and tissue transfer procedures. It has developed approximately 192 disposable instruments for use in the plastic.. Read More

Biomira, Inc., a biotechnology company, engages in the research and development of therapeutic products for the treatment of cancer primarily in the United States and Canada. It focuses on the development of synthetic vaccines for active specific immunotherapy. The company's lead cancer vaccine candidate under.. Read More

Bionovo, Inc., a clinical stage drug discovery and development company, focuses on womens health and cancer primarily in the United States. Its lead drug candidate, Menerba, is a receptor sub-type selective estrogen receptor modulator for the treatment of vasomotor symptoms of menopause. Bionovo, Inc. also develops BZL101, an oral anti-cancer agent for advanced breast cancer, as well as VG101, a preclinical drug candidate for the treatment of post-menopausal vulvar and vaginal atrophy. The company was founded in 2002 and is based in Emeryville, California.

BioProgress plc is engaged in the research, development, marketing, sales and distribution of products that use water soluble and biodegradable films for the dietary supplement, pharmaceutical and other applications. The Company also develops flushable and biodegradable products for the medical industry... Read More

Biopure Corporation offers oxygen-carrying biological drugs called oxygen therapeutics. Oxygen therapeutics are intravenously administered to deliver oxygen to the bodys tissues. Its products include Hemopure, a human drug, for use in adult surgery patients who are acutely anemic and for eliminating, delaying, or reducing allogenic red blood cell transfusions in these patients; and Oxyglobin, a veterinary drug for the treatment of anemia in dogs. Hemopure is approved for sale in South Africa. The company focuses to market Hemopure to hospitals and pre-hospital environments; and sells Oxyglobin through distributors in the United States and Europe. The company was founded in 1984 and is headquartered in Cambridge, Massachusetts.

BioSante Pharmaceuticals, Inc., a biopharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism. It develops calcium phosphate nanotechnology for aesthetic medicine, novel vaccines, and drug delivery. The companys products include LibiGel, a transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction; Elestrin, a transdermal estradiol (estrogen) gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; Bio-T-Gel, a transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency in men; and the Pill-Plus for the treatment of female sexual dysfunction in women using oral or transdermal contraceptives. The companys CaP products in development comprise BioLook, which is facial line filler in development using proprietary CaP technology in the area of aesthetic medicine; BioVant for the treatment of viral and bacterial infections and autoimmune diseases; BioOral, a delivery system using CaP technology for oral/buccal/intranasal administration of proteins and other therapies; and BioAir, a delivery system using CaP technology for inhalable versions of proteins and other therapies. The company was founded in 1996 and is based in Lincolnshire, Illinois.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for multiple indications in the United States. The company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase known as XIAFLEX for clinical indications in dupuytrens disease, peyronies disease, and frozen shoulder. The XIAFLEX is under phase IIb clinical trial for the treatment of peyronies disease. BioSpecifics Technologies also focuses on the development of collagenase for various other clinical indications, including lipomas and cellulite. The company was founded in 1957 and is headquartered in Lynbrook, New York.

Biotech Holdings, Ltd. researches, develops, manufacturers, and markets pharmaceutical, personal care and health care products. The Company markets DIAB II which is a new drug treatment for Type II Diabetes. The Company's manufacturing facility in British Columbia manufactures OTC creams, lotions, gels and salves.. Read More

BioTime, Inc., a biotechnology company, develops blood plasma volume expanders and blood replacement solutions for hypothermic (low temperature) surgery, and organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. The company, through its subsidiary,.. Read More

BioTransplant Incorporated engages in the discovery, development, and commercialization of therapeutics, therapeutic devices, and therapeutic regimens designed to suppress undesired immune responses, and enhance the bodys ability to accept donor cells, tissues, and organs. Based on its ImmunoCognance approach,.. Read More

Biovest International, Inc., a biotechnology company, develops therapeutic anti-cancer vaccine for the treatment of low-grade Follicular Lymphoma in the United States. It develops BiovaxID, a Phase III clinical trial product, which is an injectable patient-specific vaccine to treat the follicular form of non-Hodgkins lymphoma. The company develops, manufactures, and markets cell culture systems, equipment, and consumable parts to pharmaceutical, diagnostic, and biotechnology companies, as well as to research institutions worldwide. Biovest International also produces mammalian and insect cells, monoclonal antibodies, recombinant and secreted proteins, and other cell culture products using hollow fiber perfusion. It is also developing an automated cell culture instrument, AutovaxID that enables production of personalized cell-based treatments. In addition, the company sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. Further, Biovest International engages in the production and contract manufacture of biologic drugs and cell production for research institutions. Its customers include biopharmaceutical and biotech companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. The company was incorporated in 1981 as Endotronics, Inc. and changed its name to Cellex Biosciences, Inc. in 1993. Further, it changed its name to Biovest International, Inc. in 2001. The company is based in Worcester, Massachusetts. Biovest International, Inc. is a subsidiary of Accentia Biopharmaceuticals, Inc. On November 10, 2008, Biovest International Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Middle District of Florida, Tampa, in joint administration with Accentia Biopharmaceuticals, Inc.

Bridgetech Holdings International, Inc., a development stage company, focuses on the transfer of medical drugs, devices, and diagnostics primarily from the United States to China. The company also offers medical technology transfer, nurse recruitment and training, medical imaging, and electronic article.. Read More

Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada. It has two Phase III product candidates in development, which include Acetavance, a.. Read More

Cadus Corporation, through its subsidiary, Cadus Technologies, Inc., focuses on licensing yeast-based drug discovery technologies. It licenses various reagents and its library of over 30,000 yeast strains, as well as bioinformatics software. The company was formerly known as Cadus Pharmaceutical Corporation and.. Read More

Cambrex Corporation, a life sciences company, provides products and services to develop and commercialize active pharmaceutical ingredients and advanced intermediates. Its products include active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and.. Read More

CardioVascular BioTherapeutics, Inc., a development stage biopharmaceutical company, focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company uses an active pharmaceutical ingredient, the 141 acidic human form of fibroblast growth factor-1, in its.. Read More

Cardiovascular Systems, Inc., a medical device company, focuses on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360 Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360 removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company was founded in 1989 as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in 2003. Cardiovascular Systems, Inc. is based in Saint Paul, Minnesota.

Clinical development of cardiology therapeutics

Cardium Therapeutics, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of therapeutic products and devices for cardiovascular, ischemic, and related indications. Its products include Generx, a DNA-based growth factor therapeutic that is in Phase III clinical stage designed.. Read More

Cavit Sciences, Inc., a development stage biotechnology company, engages in developing treatments for cancer, viral infections, opportunistic infections, and immune enhancers. The company owns 12 patent applications, including a U.S. utility patent application relating to compositions and methods for inhibition.. Read More

Celgene Corporation engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases primarily in Europe and the United States. Its primary commercial stage products include REVLIMID for the treatment in combination with dexamethasone.. Read More

Cell Genesys, Inc. does not have significant operations. The company is evaluating strategic alternatives, including merger with or acquisition by another company, further restructuring of the company, allocation of its resources towards other biopharmaceutical product areas, sale of the companys assets, and liquidation of the company. Previously, it operated as a biotechnology company that focused on the development and commercialization of biological therapies for patients with cancer. The company terminated the VITAL-1 and VITAL-2 Phase III clinical trials of GVAX immunotherapy, its lead product program, for the treatment of prostate cancer. Cell Genesys, Inc. was founded in 1988 and is based in South San Francisco, California.

Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkins lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington.

Cellceutix Corporation operates as a development stage biopharmaceutical company in the United States. It has the rights to six different pharmaceutical compound candidates that are designed for treatment of diseases. The companys lead product candidate, Kevetrin, is used for the treatment of head and neck.. Read More

Cellcyte Genetics Corporation, a development stage biotechnology company, engages in the discovery and development of stem cell enabling therapeutic products and medical devices for cell production. It is developing clinical-stage therapeutic agents and treatments for oncology, diabetes, heart, liver, lung, and kidney diseases, as well as for stem cell bone marrow and organ transplants. The companys development-stage products include CCG-TL35 compound to deliver stem cells to repair the liver and CCG-TH30 for the delivery of autologous bone marrow-derived stem cells to repair the heart. Its therapeutic discoveries are combined with a platform of device technologies to enhance stem cell interventions and other cellular therapy approaches. Cellcyte Genetics Corporation has a collaborative research agreement with Northwestern Universitys Feinberg School of Medicine to perform an acute myocardial infarction disease model study in mice using the companys CCG-TH30 product candidate. The company was founded in 2005 and is based in Bothell, Washington.

CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. The companys lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company also develops CEL-1000, which is derived from a pre-clinical technology called Ligand Epitope Antigen Presentation System for protection for animals against avian flu, herpes, malaria, viral encephalitis, smallpox, vaccinia, and cancer, as well as CEL-2000, for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.

Ceragenix Pharmaceuticals, Inc. operates as a medical device company focusing on infectious diseases and dermatology in the United States. The company has two base technology platforms, which include Ceragenins for the treatment of infectious disease; and Barrier Repair for the treatment of dermatological.. Read More

Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The companys INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. It has collaboration agreements with Baxter International, Inc., BioOne Corporation, and Laboratorios Grifols S.A., as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California.

Champions Biotechnology, Inc. engages in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The companys Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice.. Read More

Charles River Laboratories International, Inc., together with its subsidiaries, provides solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services worldwide. It operates in two segments, Research Models and Services.. Read More

Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It offers droxidopa, an orally active synthetic precursor of norepinephrine, which is in two.. Read More

A bio-pharmaceutical company focused on developing, manufacturing and distributing innovative drugs in the People's Republic of China.

China Biopharma, Inc., through its subsidiaries, engages in the development and distribution of human vaccine products in China. It offers vaccines for flu, Japanese encephalitis, hepatitis B, allergies, and rabies. The company distributes its products directly or indirectly to hospitals, clinics, pension fund.. Read More

Clearant, Inc. engages in the development and marketing of pathogen inactivation technology in the United States. It acquires, develops, and markets its pathogen inactivation technology, the Clearant Process, to producers of biological products, such as devitalized musculoskeletal tissue allograft implants,.. Read More

Clinical Data, Inc. operates as a global biotechnology company utilizing proprietary biomarker intellectual property and expertise to develop and commercialize both targeted therapeutics and molecular diagnostic tests. Its PGxHealth division focuses on developing and commercializing targeted therapeutics and.. Read More

CombiMatrix Corporation, together with its subsidiaries, develops technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense, and homeland security. Its technologies include a platform to produce customizable, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences, and nanotechnology. The companys products and services include CustomArray platform, an oligonucleotide array for genetic studies; CatalogArray Microarrays for gene expression studies, mutation analysis, and other studies; Micro-RNA Arrays that are used to study micro-RNA molecules; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their exact specifications; stripping reagents, which enables researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. CombiMatrix also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, it develops capabilities of producing arrays that utilize bacterial artificial chromosomes that enable genetic analysis; and a series of compounds to address various oncology-related diseases. CombiMatrix sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia. The company was founded in 1995 and is based in Mukilteo, Washington. CombiMatrix Corporation (NasdaqGM:CBMX) operates independently of Acacia Research Corp. as of August 16, 2007.

CombinatoRx, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and outlicensing synergistic combination pharmaceuticals. It develops novel therapeutics with multi-target mechanisms of action that are built from combinations of drugs that utilize novel biology to treat various conditions, including immuno-inflammatory diseases, cancer, metabolic diseases, inherited diseases, and other diseases. The companys products include Synavive, a novel dissociated glucocorticoid product candidate to enhance the anti-inflammatory benefits of glucocorticoids, which completed phase II in rheumatoid arthritis, knee osteoarthritis, hand osteoarthritis, and biomarker study; CRx-401, an anti-diabetic agent, which is in phase IIa clinical study; and CRx-191, a topical synergistic combination drug candidate that has completed phase IIa clinical trials for psoriasis. Its products also include CRx-197, a novel topical anti-inflammatory product candidate that completed phase IIa clinical trials for the treatment of psoriasis, atopic dermatitis, and other inflammatory dermatoses; and CRx-170, an oral synergistic combination drug candidate, which completed phase IIa clinical trial for the potential treatment of chronic pain conditions. CombinatoRx, Incorporated has collaborations with Angiotech Pharmaceuticals, Inc.; Fovea Pharmaceuticals SA; Cystic Fibrosis Foundation Therapeutics Incorporated; CHDI, Inc.; Charleys Fund and the Nash Avery Foundation; National Institutes of Allergy and Infectious Diseases; HenKan Pharmaceutical Company; Spinal Muscular Atrophy Foundation; Sirtris Pharmaceuticals, Inc.; and Novartis AG. The company was founded in 2000 and is based in Cambridge, Massachusetts.

Compugen Ltd., an early stage drug and diagnostic discovery company, offers therapeutic and diagnostic biomarker product candidates for cancer, cardiovascular, and immune-related diseases in North America and Israel. It develops products using computer-based discovery platforms, as well as through analyzing DNA or RNA sequences, gene expression data, protein network data, data related to drugs in development, and drugs already being commercialized. Compugens validated discovery platforms include Splice Variant based Therapeutic Proteins, Nucleic-Acid Disease Markers, Protein Disease Markers, Monoclonal Antibody Targets, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, GPCR Therapeutic Peptide Ligands, New Indications, Disease-Associated Conformation Blockers, and Viral Peptides Discovery. Its therapeutic product candidates include CGEN-241, a splice variant of the MET receptor; CGEN-855, a peptide agonist of the FPRL1 GPCR receptor; CGEN-856 and CGEN-857, the MAS GPCR peptide agonists; CGEN-25007, a novel peptide antagonist of the gp96 protein; CGEN-25008, a peptide antagonist of the Clusterin protein; CGEN-25009-4, an agonist peptide of the LGR7 receptor; CGEN-54, a splice variant of the MCP-1; CGEN-34, a splice variant of the peptide ANP; and CGEN-50001, a small molecule drug. Compugens diagnostic product candidates include CGEN-144, a variant of the Troponin I biomarker; CGEN-438, a blood based biomarker for lung cancer; CGEN-6, a secreted splice variant protein; and CGEN-327, a biomarker for ovarian cancer. It also develops plant traits to the agbio industry through the use of a platform combining computational genomics, molecular biology, and breeding methods. Compugen has collaboration and license agreements with Roche; Siemens Healthcare Diagnostics, Inc.; Ortho-Clinical Diagnostics; Biosite; Teva Pharmacuetical Industries; Merck & Co.; and Medarex, Inc. The company was founded in 1993 and is based in Tel Aviv, Israel.

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the development of drugs for the treatment of severe psychiatric and metabolic disorders in the United States. The company focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its lead product includes CORLUX, a glucocorticoid receptor II, which is in Phase III clinical trials for the treatment of the psychotic features of psychotic depression and for Cushing's Syndrome. The company also focuses on other psychiatric and metabolic disorders, such as weight gain following treatment with antipsychotic medication; early dementia, including early Alzheimers disease; mild cognitive impairment; gastro esophageal reflux disease; cognitive deterioration in adults with Downs Syndrome; delirium; the prevention and treatment of stress disorders; and psychosis associated with cocaine addiction. It has exclusive patent license from Stanford University for the use of GR-II antagonists, as well as has agreements with ICON Clinical Research, LP; MedAvante, Inc.; and Eli Lilly and Company. The company was founded in 1998 and is headquartered in Menlo Park, California.

Cordex Pharma, Inc., a development stage biopharmaceutical company, focuses on developing new cardiovascular, and pulmonary diagnostic and therapeutic products based on adenosine triphosphate and nitric oxide. Its product candidates include ATPace, which is intended for the diagnosis and treatment of cardiac.. Read More

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States. Its marketed products include SPECTRACEF for the treatment of mild to moderate infections, such as.. Read More

Cougar Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition and development of therapeutics for the treatment of cancer in the United States. The companys clinical stage drug candidates include CB7630 (abiraterone acetate) for the treatment of advanced prostate cancer and.. Read More

Crucell N.V., an integrated biopharmaceutical company, focuses on the development, production, and marketing of vaccines and antibodies that prevent and treat infectious diseases. Its product portfolio comprises Quinvaxem, a liquid vaccine for five childhood diseases; Hepavax-Gene, a vaccine against hepatitis B;.. Read More

CuraGen Corporation, a biopharmaceutical development company, develops novel therapeutics for the treatment of cancer in the United States and Europe. The company focuses on the development of CR011-vcMMAE, a Phase II clinical trail drug for the treatment of patients with metastatic melanoma and breast cancer. It has strategic collaborations with Amgen Fremont to develop fully-human monoclonal antibody therapeutics; and Seattle Genetics, Inc. to license Seattle Genetics proprietary antibody- drug conjugate technology. The company was founded in 1991 and is headquartered in Branford, Connecticut.

Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor. The company was founded in 2000 and is based in Cambridge, Massachusetts.

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an.. Read More

Cypress Bioscience, Inc. provides therapeutics and personalized medicine services. The company focuses on addressing the needs of physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. It offers Savella, a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine for the management of fibromyalgia. The company provides personalized medicine services, which include tests that are validated analytically and clinically to provide physicians with actionable information to help manage their patients care, including predicting the likelihood of developing disease or optimizing therapy. Its personalized medicine services include Avise PG, a test that supports dose optimization and therapeutic decision making for patients taking methotrexate, a therapy for rheumatoid arthritis (RA); and Avise MCV, a test that aids in the diagnosis and prognosis of RA. The company has a license agreement with Pierre Fabre Medicament to develop and sell products with the compound milnacipran as an active ingredient for various indications in the United States and Canada; a collaboration agreement with Forest Laboratories, Inc. for the development and marketing of milnacipran; and a reformulation and new product agreement with Collegium Pharmaceutical, Inc. Cypress Bioscience, Inc. was founded in 1981 and is based in San Diego, California.

Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The companys lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The companys products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295. The company was founded in 1997 and is headquartered in South San Francisco, California.

Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal.. Read More

CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II.. Read More

DARA BioSciences, Inc., a development-stage pharmaceutical company, develops a portfolio of therapeutic candidates for the treatment of metabolic diseases, including type 2 diabetes and neuropathic pain. The company acquires therapeutic molecules and medical technologies from third parties and advances their.. Read More

Deltagen, Inc. provides drug discovery tools and services to the biopharmaceutical industry. It offers access to its inventory of knockout mouse lines and related phenotypic data, which enable target validation and drug discovery. In addition, Deltagen offers target validation data in the areas of immunology and.. Read More

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The companys product portfolio includes active cellular immunotherapy, monoclonal antibody, and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, and androgen-independent prostate cancer; and Neuvenge (lapuleucel-T), an investigational active immunotherapy for the treatment of patients with breast, ovarian, and other solid tumors expressing HER2/neu. The company also has a range of products in preclinical studies, which include CEA for the treatment of breast, lung, and colon cancer; CA-9 (MN) for the treatment of kidney, colon, and cervical cancer; Anti-Serine Protease for the treatment of multiple cancers; and Anti-HLA-DR for the treatment of hematologic malignancies, as well as TRPM8 for the treatment of lung, breast, prostate, and colon cancer. Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington.

Discovery Laboratories, Inc., a biotechnology company, engages in developing surfactant replacement therapies (SRT) to treat respiratory disorders and diseases. The companys proprietary technology, KL4 Surfactant Technology, produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant. Its products include Surfaxin, a synthetic, peptide-containing surfactant for use in pediatric medicine; Surfaxin (lucinactant) for the prevention of respiratory distress syndrome (RDS) in premature infants; and Aerosurf, which is a KL4 Surfactant in aerosolized form to treat premature infants at risk for RDS. Discovery Laboratories also focuses on the development of Surfaxin to address bronchopulmonary dysplasia in premature infants, acute respiratory failure in children, cystic fibrosis, acute lung injury, and other diseases associated with the inflammation of the lung, such as asthma and chronic obstructive pulmonary disease. The company has a license agreement with Philip Morris USA Inc. to use its Capillary Aerosolization Technology for use with pulmonary surfactants for the respiratory diseases; and has a strategic alliance with Laboratorios del Dr. Esteve, S.A. to develop, market, and sell surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories was founded in 1992 and is headquartered in Warrington, Pennsylvania.

DocPlanet.com, Inc. is a business-to-business e-commerce company that provides pharmaceuticals to office-based physicians. The Company provides thousands of physicians with an online partner for pharmaceutical products and related software in hundreds of locations across the United States. In December 2000, the.. Read More

DOR BioPharma, Inc., a biopharmaceutical company, focuses on the development of products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and biodefense vaccines in the United States and internationally. The company operates through two segments, BioTherapeutics.. Read More

A pharmaceutical company, which focuses on manufacturing and marketing of antibiotic drugs. It has three business units: Chemical Division for manufacturing, Pharma Division for manufacturing and Biotech Division for EPO.

Dyax Corp., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of biotherapeutics for oncology and inflammatory indications. The company uses phage display, a drug discovery technology to identify antibody, small protein, and peptide compounds for clinical.. Read More

Eisai Co., Ltd., with 34 subsidiaries and three associated companies, is a Japanese human healthcare company, based in Tokyo. The Company engages in the research and development, manufacture and marketing of pharmaceutical drugs and over-the-counter drugs. It also produces and offers food additives, chemicals and.. Read More

Emergent BioSolutions Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of vaccines and immune-related therapeutics in the United States, the United Kingdom, and Vietnam. The company offers BioThrax, a vaccine for preventing anthrax infection. Its advanced stage product candidates, which are in Phase II through Phase IV clinical development, include Recombinant protective antigen vaccine that comprises a purified recombinant protein with an alum adjuvant; Anthrax Immune Globulin therapeutic for the treatment of symptomatic anthrax infection; tuberculosis vaccine to prevent tuberculosis; Typhella which is a single-dose, drinkable vaccine for typhoid; Hepatitis B therapeutic vaccine for treating chronic carriers of hepatitis B infection. The companys earlier stage development product candidates comprise advanced BioThrax vaccine; Anthrax monoclonal antibody therapeutic, a human monoclonal antibody therapeutic for patients who present symptoms of anthrax disease; Recombinant botulinum vaccine to protect against illness caused by botulinum toxin; and Chlamydia vaccine for administration to adolescents to prevent disease caused by clinically relevant strains of Chlamydia trachomatis. Emergent BioSolutions Inc. has collaborations with Sanofi Pasteur and United Kingdom Health Protection Agency. The company was founded in 1998 and is based in Rockville, Maryland.

EntreMed, Inc., a clinical-stage pharmaceutical company, develops therapeutic candidates primarily for the treatment of cancer and inflammation. The companys clinical development products include ENMD-2076, an Aurora A and angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases; used to treat tumor regression in various xenograft models, such as breast, colon, and leukemia; an activity towards ex vivo-treated human leukemia patient cells; and in Phase 1 clinical studies to treat solid tumors and multiple myeloma. Its clinical development products also include MKC-1, an oral cell-cycle inhibitor with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for metastatic breast, non-small cell lung, leukemia, pancreatic, ovarian/endometrial, and solid cancer tumors; ENMD-1198, an antimitotic agent currently in Phase 1 studies that induces cell cycle arrest and apoptosis in tumor cells; and Panzem, a Phase 1 clinical trial candidate for the treatment of rheumatoid arthritis. The company has license agreements with Childrens Hospital Medical Center Corporation and Celgene Corporation. EntreMed, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing, manufacturing, and commercializing medicines for patients with cancer and other life-threatening conditions in the United States and internationally. Its products include Oncaspar, a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia; and DepoCyt, an injectable chemotherapeutic agent for the treatment of patients with lymphomatous meningitis. The company also offers Abelcet, a lipid formulation of amphotericin B used to treat immuno-compromised patients with invasive fungal infections; and Adagen, a PEGylated bovine adenosine deaminase enzyme (ADA) used to treat patients afflicted with a type of severe combined immunodeficiency disease, which is caused by the chronic deficiency of ADA. In addition, it licenses its PEGylation platform for products, such as PEG-INTRON, Pegasys, Macugen, and CIMZIA; and provides contract manufacturing services for various injectable products. Enzon is also developing PEG-SN38 for the treatment of colorectal, breast, and pancreatic cancer, as well as for non-Hodgkins lymphoma; and HIF-1 alpha antagonist for the treatment of cancers and common solid tumors. Further, it offers Recombinant Human Mannose-Binding Lectin, a protein therapeutic to prevent and treat severe infections in individuals with low levels of MBL; and provides contract manufacturing services for various injectable products. The company has development and commercialization agreements with Santaris Pharma A/S; Schering-Plough; Sanofi-Aventis; Medac; Micromet; NatImmune A/S; Nektar; Pacira; and Cephalon France SAS. It markets its therapeutic products through its sales force that includes specialists in oncology, hematology, infectious disease, and various critical care disciplines. The company was founded in 1981 and is based in Bridgewater, New Jersey.

EPIX Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics through the use of its proprietary silico drug discovery technology to treat diseases of the central nervous system and lung conditions. Its therapeutic product candidates in development include PRX-03140, which completed Phase II clinical trials for the treatment of Alzheimers disease; PRX-08066, a small-molecule inhibitor that completed Phase II clinical trials for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with chronic obstructive pulmonary disease; and PRX-07034, which completed Phase I studies for the treatment of cognitive impairment associated with schizophrenia. The company also offers Vasovist, an injectable intravascular contrast agent to provide enhanced imaging of the vascular system using magnetic resonance angiography. It has collaborations with SmithKline Beecham Corporation, Amgen Inc., and Cystic Fibrosis Foundation Therapeutics, Incorporated. The company was formerly known as EPIX Medical, Inc. and changed its name to EPIX Pharmaceuticals, Inc. in 2004. EPIX Pharmaceuticals, Inc. was founded in 1988 and is based in Lexington, Massachusetts.

Eurand N.V., a specialty pharmaceutical company, develops, manufactures, and commercializes pharmaceutical and biopharmaceutical products. The company develops these products based on its proprietary customized release technologies used to reduce daily dosing requirements and time the release of drugs in the body.. Read More

EXACT Sciences Corporation develops DNA-based technologies for use in the detection of various cancers in the United States. It offers ColoSure, a non-invasive laboratory developed stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. The company has a strategic.. Read More

Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical.. Read More

Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and.. Read More

Forbes Medi-Tech, Inc. engages in the research, development, and commercialization of products for the prevention and treatment of cardiovascular and related diseases. The company develops cholesterol-lowering agents for use in pharmaceutical compounds, functional foods, and dietary supplements. Its lead drug.. Read More

Forticell Bioscience, Inc. operates as a development stage tissue engineering company. It focuses on biology, biomaterials, and cell culturing activities. The company has developed a proprietary and patented product, OrCel, which is used to stimulate the repair and regeneration of human skin. OrCel is a.. Read More

GalaGen Inc. is engaged in the development of foods, beverages and dietary supplements that help enhance the immune system and take advantage of all of the benefits offered by colostrum. The Company is focusing its efforts on channels that demand immune-enhancing benefits in certain segments of the consumer food.. Read More

A life science company focused on the development of immunotherapy and related approaches to treat cancer.

Genaera Corporation, a biopharmaceutical company, engages in the research and development of medicines to address the obesity, type 2 diabetes, and respiratory diseases. The companys lead clinical drug candidate, Trodusquemine, a small molecule in Phase I trials to treat obesity and type 2 diabetes. Its products also comprise anti-interleukin-9, a Phase II clinical testing product for the treatment of asthma; and LOCILEX cream, a topical cream antibiotic, which is in Phase III clinical trials for the treatment of infection in diabetic foot ulcers. It has a collaborative agreement with MedImmune, Inc. to develop and commercialize therapies related to the companys anti-interleukin-9 program for the treatment of asthma. Genaera Corporation was founded in 1987 and is headquartered in Plymouth Meeting, Pennsylvania.

Develops and markets products specializing in the application of the latest discoveries in cellular and molecular immunology and cancer biology to the development of proprietary therapeutics aimed at the treatment and eradication of cancer.

Genetic Technologies Limited, a life science company, focuses on the fields of genetics and genomics primarily in Australia. It commercializes and licenses intellectual property relating to non-coding DNA. The company owns patents in the areas of human, animal and plant genetic diagnostics, and genomics. Genetic.. Read More

Genitope Corporation, a biotechnology company, engages in the research and development of immunotherapies for the treatment of cancer in the United States. Immunotherapies are treatments that utilize the immune system to combat diseases. It develops a panel of monoclonal antibodies for the treatment of.. Read More

GeNOsys, Inc., a medical research and development company, specializes in pharmaceutical, biotechnical, and medical gas generating systems. Nitric oxide gas is one of the medical gases generated along with various combinations of beneficial medical gases suitable for the control of human disease. The company.. Read More

Genta Incorporated operates as a biopharmaceutical company with a diversified product portfolio that is focused on delivering products for the treatment of patients with cancer. Its research portfolio consists of two programs, DNA/RNA Medicines and Small Molecules. The companys lead compound from its DNA/RNA.. Read More

GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III pivotal trial for first-line treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic, which is under various clinical trials for the treatment of various cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, it is developing TherAtoh, a preclinical program involving the delivery of the human atonal gene for the production of therapeutic proteins by cells in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and HSV-2. It has various strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATHS malaria vaccine initiative, the U.S. naval medical research center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The company was founded in 1992 and is based in Gaithersburg, Maryland.

Genzyme Corporation operates as a biotechnology company worldwide. The companys Genetic Diseases segment manufactures and distributes therapeutic products, including Cerezyme as an enzyme replacement therapy for the treatment of Type 1 and Type 3 Gaucher diseases; Fabrazyme, a recombinant form of the human enzyme alpha- galactosidase for the treatment of Fabry disease; Myozyme as a therapy for Pompe disease; and Aldurazyme for the treatment of Mucopolysaccharidosis I. This segment markets and sells its products directly to physicians, hospitals, treatment centers, pharmacies, and government agencies through distributors. Its Cardiometabolic and Renal segment develops, manufactures, and distributes products consisting of Renagel and Renvela for the control of serum phosphorus in patients with chronic kidney disease on dialysis; Hectorol, a line of vitamin D2 pro-hormone products for the treatment of secondary hyperparathyroidism; and Thyrogen, an adjunctive diagnostic agent used in the follow-up of patients with well-differentiated thyroid cancer. This segment sells its products to retail pharmacies, hospitals, and other providers of medication to patients. The companys Biosurgery segment provides biotherapeutics and biomaterial-based products, which comprise Synvisc, a biomaterial-based product that is used to treat the pain associated with osteoarthritis of the knee; and Sepra family of products to prevent adhesions following various surgical procedures in the abdomen and pelvis. Its Hematologic Oncology segment develops products for the treatment of cancer, which include Campath for the treatment of B-cell chronic lymphocytic leukemia; Clolar for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia; and Mozobil for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The company was founded in 1981 and is based in Cambridge, Massachusetts.

A development stage biotechnology company engaged in research and development activities with a mission to develop, license and commercialize the manufacture and sale of human vaccines for diseases caused by HIV and other infectious agents.

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases. Its products include Truvada, Viread, Atripla, and Emtriva for the treatment of human immunodeficiency virus infection in.. Read More

Gliatech Inc. is engaged in the discovery and development of biosurgery and pharmaceutical products. The biosurgery products include Adcon-L, Adcon-T/N and Adcon Solution, which are proprietary, resorbable, carbohydrate polymer medical devices designed to inhibit scarring and adhesions following surgery. In March.. Read More

GlycoGenesys, Inc. engages in the research and development of carbohydrate-based products, as well as related technologies in the area of oncology. Its lead product candidate includes GCS-100, a phase II clinical trial product, which would be used for the treatment of solid tumors and bloodborne cancers. The.. Read More

GPC Biotech AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of anticancer drugs in Germany. The company also develops genomics and proteomics technologies that comprises gene expression analysis, protein-protein interaction analysis, and bioinformatic tools, as well.. Read More

GTC Biotherapeutics, Inc. engages in the development and production of human therapeutic proteins through transgenic technology. The company is developing a portfolio of recombinant blood proteins based on its technology to treat a range of genetic and acquired blood deficiencies, including hemophilia and other blood coagulation disorders. Its product includes ATryn, a recombinant form of human antithrombin for the treatment of hereditary antithrombin deficiency (HD) patients undergoing surgery or childbirth. The companys products in development stage comprise rhFVIIa, a recombinant human coagulation factor VIIa for the treatment of hemophilia; rhFIX, a recombinant human factor IX for the treatment of type B hemophilia; rhAAT, a recombinant form of human alpha-1 antitrypsin as an inhibitor of elastase; and CD20 MAb, an immune system receptor. In addition, it develops CD137 Antibody for use in various clinical applications, including cancer and autoimmune diseases. GTC Biotherapeutics has strategic collaborations with OVATION Pharmaceuticals, Inc. to develop and market ATryn in the United States; LFB Biotechnologies S.A.S.U. to develop recombinant plasma proteins and monoclonal antibodies; and LEO Pharma A/S for the commercialization of ATryn in HD in Europe, Canada, and the Middle East, as well as an agreement with JCOM to develop recombinant human insulin products in Asia. The company was founded in 1993 and is based in Framingham, Massachusetts.

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle loss, and other serious medical conditions in the United States. It markets FARESTON tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors. The company develops toremifene citrate, a selective estrogen receptor modulator, which completed pivotal Phase III clinical trial for the prevention of bone fractures and treatment of other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia (PIN), which is in pivotal Phase III clinical trial. It also develops Ostarine, which completed Phase II clinical trial for the treatment of cancer cachexia; GTx-758, an oral luteinizing hormone, which is in Phase I clinical trial for the treatment of advanced prostate cancer; and MK-0773, which is in Phase II clinical trial for the treatment of sarcopenia. In addition, GTxs preclinical pipeline includes GTx-878, an estrogen receptor beta agonist. The company has strategic collaboration with Merck & Co., Inc. to discover and develop selective androgen receptor modulators; license and supply agreement with Orion Corporation to develop and commercialize products containing toremifene; and a collaboration and license agreement with Ipsen Group that provides Ipsen Group the rights to develop and commercialize toremifene in the European territory. It also has collaborations with Hybritech, Inc.; MacroArray Technologies, LLC; and Gen-Probe, Incorporated to develop an accurate blood or urine test to detect high grade PIN. The company was founded in 1997 and is headquartered Memphis, Tennessee.

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of products targeting the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company develops products that are based on intellectual property covering the family of human enzymes, known as hyaluronidases. Its Enhanze Technology is a drug delivery platform designed to increase the absorption and dispersion of biologic targets. Halozyme Therapeutics product candidates include Cumulase, an ex vivo formulation for use in in-vitro fertilization, as well as to replace the bovine enzyme used for the preparation of oocytes (eggs) prior to IVF during the process of intracytoplasmic sperm injection; Hylenex, a human recombinant formulation to facilitate the absorption and dispersion of other injected drugs or fluids; and Chemophase, an investigative chemoadjuvant designed to enhance the transport of chemotherapeutic agents to tumor tissue. The company has partnerships with Roche to apply Enhanzetm Technology to Roches biological therapeutic compounds; and with Baxter to apply Enhanze Technology to Baxters biological therapeutic compound, GAMMAGARD LIQUID 10%. Halozyme Therapeutics was founded in 1998 and is based in San Diego, California.

Hana Biosciences, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. The company develops Optisome encapsulated formulation product candidates and a supportive care product candidate. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. Its Optisome encapsulated formulation product candidates include Marqibo, a vincristine sulfate liposomes injection for the treatment of adult acute lymphoblastic leukemia and metastatic uveal melanoma; Brakiva, a topotecan liposomes injection for the treatment of solid tumors, including small cell lung cancer and ovarian cancer; and Alocrest, a vinorelbine liposomes injection, which is used in the treatment of non-small cell lung cancer. The companys supportive care product candidate comprises Menadione Topical Lotion, a novel supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, which are used in the treatment of lung, colon, head and neck, and pancreatic cancer. Hana Biosciences has license agreements with Tekmira Pharmaceuticals Corporation; University of British Columbia; Elan Pharmaceuticals, Inc.; Albert Einstein College of Medicine of Yeshiva University; and NovaDel Pharma, Inc. The company was founded in 2000 and is based in South San Francisco, California.

Harvard Scientific Corp. is a development-stage biopharmaceutical company with two lines of business. The Company utilizes medically researched and developed drug substances, determines the ability of these substances to be encapsulated in liposomes and determines the potential market for such products. Through.. Read More